Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy

Mesude Bicak, Katharina Lückerath, Teja Kalidindi, Michael E. Phelps, Sven Erik Strand, Michael J. Morris, Caius G. Radu, Robert Damoiseaux, Mari T. Peltola, Norbert Peekhaus, Austin Ho, Darren Veach, Ann Christin Malmborg Hager, Steven M. Larson, Hans Lilja, Michael R. McDevitt, Robert J. Klein, David Ulmert

Research output: Contribution to journalArticlepeer-review


Hu11B6 is a monoclonal antibody that internalizes in cells expressing androgen receptor (AR)-regulated prostate-specific enzyme human kallikrein-related peptidase 2 (hK2; KLK2). In multiple rodent models, Actinium-225-labeled hu11B6-IgG1 ([225Ac]hu11B6-IgG1) has shown promising treatment efficacy. In the present study, we investigated options to enhance and optimize [225Ac]hu11B6 treatment. First, we evaluated the possibility of exploiting IgG3, the IgG subclass with superior activation of complement and ability to mediate FC-γ-receptor binding, for immunotherapeutically enhanced hK2 targeted α-radioimmunotherapy. Second, we compared the therapeutic efficacy of a single high activity vs. fractionated activity. Finally, we used RNA sequencing to analyze the genomic signatures of prostate cancer that progressed after targeted α-therapy. [225Ac]hu11B6-IgG3 was a functionally enhanced alternative to [225Ac]hu11B6-IgG1 but offered no improvement of therapeutic efficacy. Progression-free survival was slightly increased with a single high activity compared to fractionated activity. Tumor-free animals succumbing after treatment revealed no evidence of treatment-associated toxicity. In addition to up-regulation of canonical aggressive prostate cancer genes, such as MMP7, ETV1, NTS, and SCHLAP1, we also noted a significant decrease in both KLK3 (prostate-specific antigen ) and FOLH1 (prostate-specific membrane antigen) but not in AR and KLK2, demonstrating efficacy of sequential [225Ac]hu11B6 in a mouse model.

Original languageEnglish
Pages (from-to)15172-15181
Number of pages10
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number26
Publication statusPublished - 2020

Subject classification (UKÄ)

  • Medical Genetics
  • Cancer and Oncology
  • Other Physics Topics

Free keywords

  • 225Ac
  • hK2
  • hu11B6
  • prostate cancer
  • radiommunotherapy


Dive into the research topics of 'Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy'. Together they form a unique fingerprint.

Cite this